Fierce Biotech – Enyo Pharma’s NASH results show boost in kidney function, differentiating vonafexor from busy field

https://www.fiercebiotech.com/biotech/enyo-pharma-s-nash-results-show-boost-kidney-function-differentiating-vonafexor-from-busy

Published on 29/07/2021

ENYO Pharma Announces Positive Vonafexor (EYP001) Results for the LIVIFY Phase 2a Study in F2-F3 NASH Patients over 12 weeks

Lyon, France. July 28, 2021 – ENYO Pharma, a private clinical stage biotechnology company developing innovative drug candidates, today announced that Vonafexor met the primary and several secondary endpoints in the LIVIFY clinical study conducted in F2-F3 Non Alcoholic Steato-Hepatitis (NASH) patients.

Read more »

Published on 28/07/2021

The Liver Meeting / AASLD 2021

12-15 November, 2021
Hybrid edition

ENYO Pharma will attend the 2021 edition of AASLD / The Liver meeting.

Read more »

Published on 09/07/2021

HBV-TAG 2021 Conference (Sponsorship)

11-12 June 2021
Virtual Conference

ENYO Pharma has sponsored the 2021 Inaugural Virtual Hepatitis B – Therapeutic Agents Conference.
www.hbv-tag.org

“The primary objective of the Virtual HBV-TAG Conference is to meet the educational needs of research and development stakeholders and healthcare professionals who seek to improve the lives of patients with HBV. The aim of the HBV-TAG conference is to bring together key opinion leaders from the teams of clinicians that care for patients with HBV (hepatologists and gastroenterologists) and pharmaceutical industry representatives to discuss optimized trial design,

Read more »

Published on 18/05/2021

ENYO Pharma featured in Biomim’BOOK 2021

ENYO Pharma is featured in the 2021 edition of Biomim’BOOK, the first book dedicated to actors and stakeholders in Biomimetism and Bio-inspiration.
To see the full book: https://www.flickr.com/photos/biomimexpo/sets/72157718879047022/
To see ENYO Pharma double page: BIOMIM_BOOK 2021_ENYO PHARMA

Read more »

Published on 07/05/2021